Q1 Earnings Estimate for COCP Issued By Zacks Small Cap

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Investment analysts at Zacks Small Cap issued their Q1 2025 earnings per share (EPS) estimates for Cocrystal Pharma in a report released on Tuesday, April 1st. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.85) per share. Zacks Small Cap also issued estimates for Cocrystal Pharma’s Q2 2025 earnings at ($0.44) EPS, FY2025 earnings at ($1.65) EPS and FY2026 earnings at ($1.42) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Cocrystal Pharma in a research report on Wednesday, January 22nd.

Cocrystal Pharma Trading Up 0.7 %

Shares of NASDAQ:COCP opened at $1.43 on Thursday. Cocrystal Pharma has a 12 month low of $1.35 and a 12 month high of $3.26. The stock has a market cap of $14.55 million, a P/E ratio of -0.77 and a beta of 2.35. The company has a 50 day moving average of $1.77 and a 200 day moving average of $1.92.

Cocrystal Pharma (NASDAQ:COCP) last posted its earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.23.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.